TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.
TAKHZYRO
Quick Start Program
Shire will provide eligible patients with immediate access to TAKHZYRO at no cost during potential delays in commercial insurance coverage determinations*
This program is available to all patients who meet the following criteria:
-
≥12 years old with confirmed diagnosis of HAE
-
Received a prescription for TAKHZYRO
-
Commercially insured in the US
To enroll your patients in the Quick Start Program, a commercial insurance investigation must be initiated by filling out the TAKHZYRO Start Form.
*Timing is dependent upon when the forms are received by OnePath®.
Shire and its affiliates reserve the right to change or discontinue this program at any time, without notice. Void where prohibited by law. This program does not constitute a financial assistance program.
2 simple steps
To get your patients started right away
-
1. Print and fill out these 2 FORMS completely:
-
2. Fax BOTH forms to OnePath
1-855-ONEPATH (663-7284)
Once BOTH forms are received by OnePath:
-
1
Your patient’s dedicated Patient Support Manager will call your patient promptly to:
- Confirm all forms are complete
- Coordinate shipment of TAKHZYRO
- Schedule in-home self-administration training led by a specially trained nurse, if requested
-
2
The benefits investigation will be conducted. Prior authorization/appeal, if required, will begin.
-
3
A 1-month supply of TAKHZYRO will be shipped to your patient once eligibility requirements have been confirmed and the specialty pharmacy verifies the prescription with your office†
Once your patient's commercial insurance coverage for TAKHZYRO is approved, he/she will no longer be eligible for the Quick Start Program.
†Once eligibility has been confirmed, a 1-month supply of TAKHZYRO will be shipped to your patient. Patients are eligible for up to 2 months of product at no cost, with the potential for an approval process for continued supply of the product after the second month.
Note that insurance companies sometimes require additional documentation to authorize coverage for TAKHZYRO, which could include:
INDICATION
TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.
IMPORTANT SAFETY INFORMATION
Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.
Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.
Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.
No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.
To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp. (a wholly-owned, indirect subsidiary of Shire plc) at 1–800–828–2088, or FDA at 1–800–FDA–1088 or www.fda.gov/medwatch.
Please see full Prescribing Information here.